Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Table 3 Prevalence of ARV change, crude and adjusted odds ratios (with 95%CI) summarizing the relationship between selected risk factors and ARV change during a 48 week follow-up period among HIV-infected children in Uganda (N = 142)

Characteristic	ARV changed by week				Crude Odds Ratio	Adjusted Odds Ratio
Characteristic	12 n (%)	24 n (%)	36 n (%)	48 n (%)	OR (95% CI)	OR (95% CI)
Overall	2 (1)	10 (8)	12 (9)	23 (17)
Monitoring arm
Immunologic	–	3 (5)	–	9 (14)	Ref	Ref
Virologic	2 (3)	7 (11)	12 (18)	14 (21)	1.52 (0.59; 3.89)	1.58 (0.62; 4.00) ^a
^∫log (HIV RNA copies/ml)					0.97 (0.90; 1.05)	1.02 (0.92; 1.12)^a
^∫Log (ABS CD4)					0.91 (0.44; 1.86)	0.77 (0.29; 2.00)^b
^∫CD4%					0.99 (0.96; 1.04)	0.97 (0.92; 1.04)^b
Week
Baseline					Ref	Ref^*
24					1.91 (1.19; 3.07)	5.37 (3.02; 7.97) ^a
48					3.65 (1.40; 9.45)	24.10 (9.14; 63.56) ^a

*p < 0.05; **p < 0.01
Participants who had an ARV change are counted in the prevalence estimate at subsequent follow-up
^a Covariates in the final adjusted model: log (HIV RNA copies/ml), study arm, week, NVP exposure, ART duration, and location
^b Covariates in the final adjusted model: study arm, week, NVP exposure, ART duration, and location
^∫Time dependent variable

ISSN: 1471-2431